Molazepam
Reading File
Searching the Web
molazepam benzodiazepine drug
Finding Sources
Searching the Web
molazepam drug pharmacology
Molazepam does not appear in any medical textbook in the library, nor in standard drug databases or pharmacology references. Both searches consistently return results for lorazepam instead.
There are a few possibilities:
-
Spelling variation or typo — Did you mean one of these?
- Lorazepam (Ativan) — a widely used benzodiazepine for anxiety, sedation, and seizures
- Midazolam — a short-acting benzodiazepine used for procedural sedation and anesthesia
- Clonazepam — a benzodiazepine used for seizures and panic disorder
- Bromazepam or Oxazepam — other benzodiazepine agents
-
Regional/brand name — It could be a brand or trade name used in a specific country that isn't widely indexed in international databases.
-
Investigational compound — It may be a research-stage or obscure chemical entity not in mainstream references.
Could you clarify what you're looking for? For example:
- Are you asking about a specific drug you encountered (prescription, package insert, etc.)?
- Is this a possible spelling variation of another benzodiazepine?
With the correct name, I can provide full pharmacology, indications, dosing, and clinical details.
Midalozam
Finding Sources
Searching the Web
midazolam pharmacology mechanism uses dosing
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information. Here is a full summary of Midazolam:
Midazolam (Versed)
Class & Overview
Midazolam is a short-acting, water-soluble benzodiazepine with anxiolytic, sedative, hypnotic, amnesic, anticonvulsant, and muscle-relaxant properties. It is the most widely used benzodiazepine in perioperative and procedural medicine.
Mechanism of Action
Midazolam acts selectively at the GABA-A receptor — a pentameric, ligand-gated chloride ion channel. It binds to the benzodiazepine site (distinct from the GABA binding site) and acts as a positive allosteric modulator, enhancing GABA-mediated chloride channel opening → neuronal hyperpolarization → CNS depression.
Different effects are mediated by different GABA-A subunits:
- α₁ subunit → sedation, anterograde amnesia, anticonvulsant effect
- α₂ subunit → anxiolysis and muscle relaxation
Midazolam is approximately 3–6× more potent than diazepam (receptor affinity order: lorazepam > midazolam > diazepam).
Pharmacokinetics
| Parameter | Value |
|---|---|
| Oral bioavailability | <50% (significant first-pass metabolism) |
| Peak plasma level (oral) | 30–80 minutes |
| Protein binding | 94–98% |
| Volume of distribution | Increased in obesity |
| Elimination half-life | 1.7–3.5 hours (up to 5.4 h in critically ill) |
| Plasma clearance | 5.8–9.0 mL/kg/min |
| Metabolism | Hepatic via CYP3A4 and CYP3A5 |
| Active metabolites | 1-hydroxymethylmidazolam (α-OH-midazolam), 4-hydroxymidazolam |
| Excretion | Urine (conjugated metabolites) |
Special populations:
- Neonates/premature infants — reduced clearance; use with caution
- Obese patients — larger volume of distribution → prolonged half-life
- Liver cirrhosis — reduced clearance
- Renal impairment — metabolites can accumulate → profound sedation
Clinical Uses
1. Premedication (Pre-op anxiety/amnesia)
- Most commonly used benzodiazepine for premedication in adults and children
- Adult oral dose: 7.5–15 mg
- Pediatric: 0.025 mg/kg (sedation/anxiolysis in 10–20 minutes); well-tolerated intranasally or buccally
- Effects: anxiolysis, anterograde amnesia, sedation (retrograde memory unaffected)
2. Procedural Sedation
- IV titration to dysarthria or desired sedation level
- Peak effect: 2–3 minutes after IV administration
- Patients appear conscious but are amnesic to the procedure
- Plasma levels for hypnosis/amnesia: 100–200 ng/mL; awakening at <50 ng/mL
3. Induction/Maintenance of General Anesthesia
- Induction dose: 0.1–0.4 mg/kg IV
- Synergistic with propofol and thiopental for induction; additive with ketamine
4. ICU Sedation (mechanically ventilated patients)
- Continuous infusion used; risk of accumulation in prolonged use
5. Acute Seizures / Status Epilepticus
- Intranasal or buccal route preferred in children (0.2–0.3 mg/kg)
- Shown superior to rectal diazepam in pediatric seizures
6. Prevention of PONV
- Midazolam has a role in postoperative nausea and vomiting prophylaxis
Organ System Effects
CNS: Dose-related reduction in cerebral metabolic rate (CMRO₂). Neuroprotective (prevents lipid peroxidation, mitochondrial damage). Raises seizure threshold to local anesthetics.
Respiratory: Dose-related central respiratory depression; flattens CO₂ response curve; depresses hypoxic ventilatory response; increases risk of upper airway obstruction. Risk greatly enhanced with opioids (synergistic/additive).
Cardiovascular: Minimal hemodynamic effects alone — modest decrease in arterial BP via reduced systemic vascular resistance. In elevated LV filling pressures, produces a "nitroglycerin-like" effect (↓ filling pressure, ↑ cardiac output).
Drug Interactions
- CYP3A4 inhibitors (azole antifungals, macrolides, HIV protease inhibitors) — markedly ↑ midazolam levels; oral midazolam especially affected (first-pass inhibition)
- Opioids — synergistic respiratory and CNS depression; can cause severe hypotension especially in neonates
- Propofol / thiopental — synergistic hypnotic interaction
- Ketamine — additive interaction
- Ethanol and CNS depressants — additive CNS depression
Reversal
Flumazenil (benzodiazepine antagonist) — competitively blocks benzodiazepine binding sites on GABA-A receptor, reversing sedation. Note: shorter half-life than midazolam, so resedation may occur.
Contraindications
- Myasthenia gravis
- Acute alcohol intoxication
- Narrow-angle glaucoma
- Known hypersensitivity
Sources: Miller's Anesthesia, 10e; Barash's Clinical Anesthesia, 9e; Katzung's Basic & Clinical Pharmacology, 16e
This is a shared conversation. Sign in to Orris to start your own chat.